Corvus Pharmaceuticals Reports $17.96 Million Net Loss in Q2 2026, Total Assets Reach $239.27 Million

Corvus Pharmaceuticals, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $17.96 million for the quarter, compared to a loss of $7.99 million in the same period last year. For the first half of 2026, the net loss totaled $31.65 million, a stark contrast to a net income of $7.20 million reported for the first half of 2025, which included a one-time gain from the change in fair value of warrant liability. The company's total operating expenses rose to $19.30 million for the second quarter of 2026, up from $10.26 million in the prior year, driven primarily by increased research and development costs associated with its lead product candidate, soquelitinib.

The company’s financial position has improved significantly, with total assets increasing to $239.27 million as of June 30, 2026, compared to $71.12 million at the end of 2025. This growth is largely attributed to a follow-on public offering completed in January 2026, which generated approximately $189.4 million in net proceeds. Cash and cash equivalents, along with marketable securities, amounted to $215.2 million, providing a solid liquidity cushion for ongoing operations. The accumulated deficit has reached $443.94 million, reflecting the company's continued investment in research and development without generating revenue from product sales.

Operationally, Corvus Pharmaceuticals has made strides in advancing its clinical programs. The company is currently enrolling patients in a Phase 3 clinical trial for soquelitinib, targeting relapsed peripheral T cell lymphomas, and has initiated a Phase 2 trial for atopic dermatitis. The company’s research and development expenses for the second quarter of 2026 were $15.96 million, a significant increase from $7.87 million in the same quarter of 2025, primarily due to heightened clinical trial activities. The company also reported a loss from its equity method investment in Angel Pharmaceuticals, amounting to $0.71 million for the quarter.

Looking ahead, Corvus Pharmaceuticals anticipates continued operating losses as it progresses through clinical trials and seeks regulatory approvals for its product candidates. The company has indicated that it will require additional capital to fund its operations and development programs, which may include public or private equity offerings and collaborations. Management believes that the current cash resources will be sufficient to support operations into the second quarter of 2028, but acknowledges the need for ongoing fundraising efforts to sustain its long-term objectives.